A Case Study on Berger’s Disease

Sonia Singh¹, S Sai Balaji Iyer², Prithvika wagle³

1 Asst. Professor, Department of Pharmacy Practice, College of Pharmaceutical Sciences, Dayananda Sagar University, Bengaluru -560078, India.
2,3 Interns Pharm.D, Department of Pharmacy Practice, College of Pharmaceutical Sciences, Dayananda Sagar University, Bengaluru -560078, India.

*Corresponding author’s E-mail: soniapb6895@gmail.com

Received: 18-01-2023; Revised: 20-02-2023; Accepted: 27-02-2023; Published on: 15-03-2023.

ABSTRACT

IgA nephropathy, also known as Berger’s disease, is characterized by predominant IgA deposition in the glomerular mesangium. A patient of 31-year-old male who is a known case of CKD stage 5 on regular Haemodialysis, IgA nephropathy seizure disorder, and Hypertension (for seven years) on treatment presented to the emergency. The confirmatory diagnosis was an acute febrile illness, lower respiratory tract infection, bilateral pneumonia, severe anaemia, chronic kidney disease stage 5, IgA nephropathy, seizure disorder, and accelerated hypertension. Meanwhile, he was dialyzed adequately as a life-saving treatment along with other life supportive measures.

Keywords: IgA, Berger disease, Nephropathy, Haemodialysis, Glomerular mesangium.

INTRODUCTION

IgA nephropathy, also known as Berger’s disease, is characterized by predominant IgA deposition in the glomerular mesangium. In 1968, Berger and Hinglais provided the first description. It is one of the most typical causes of glomerulonephritis worldwide¹. Most IgA nephropathy cases are idiopathic, but a respiratory tract infection frequently precedes the onset or worsening of the condition. There have been reports of associations with certain bacteria, including Haemophilus influenzae. Other reasons include liver cirrhosis, gluten enteropathy (celiac disease), HIV infection, and familial IgA nephropathy ². Patients with IgA nephropathy may not present any symptoms, yet they frequently have high blood pressure, chronic microscopic hematuria, and proteinuria. Adults are the most common demographic for this presentation. In such circumstances, renal function may be impaired, and remission is unusual. Proteinuria (less than 3 gm/day more common), nephrotic syndrome (more than 3.5gms of proteinuria with edema, hypoalbuminemia, hypertension, and hyperlipidemia), and chronic renal failure are among the symptoms of the condition³.

Starting with galactose-deficient IgA1, which has less than a full complement of galactose residues on the O-glycans in the hinge region of heavy chains, IgA nephropathy appears to be the result of an ordered series of events. These may function as auto-antigens that cause the development of glycan-specific antibodies and the synthesis of circulating immune complexes that are deposited in the renal mesangium. By releasing pro-inflammatory cytokines, secreting chemokines, and causing macrophages to migrate into the kidney, they eventually cause glomerular damage. Immune complexes, including galactose-deficient IgA and IgG, cause glomerular deposition ⁴. The only medications now available to alter mesangial IgA deposition are those that have been extrapolated from the therapy of other forms of chronic glomerulonephritis. Since there are still no randomized controlled trials in IgA Nephropathy pertinent to contemporary clinical practise, there is still no consensus on the use of immunosuppressive drugs for treating progressive IgA Nephropathy. No specific treatment is needed for patients with recurrent macroscopic haematuria or isolated microscopic haematuria and proteinuria <1 g/24 h. Patients with nephrotic syndrome and minimal change on a renal biopsy should be treated as those with minimal change nephropathy. The use of corticosteroids for nephrotic IgA Nephropathy outside this subset of individuals is not supported by any data ⁵.

Case Presentation

A patient of 31-year-old male who is a known case of CKD stage 5 on regular Hemodialysis, IgA nephropathy seizure disorder, and Hypertension (for seven years) on treatment presented to the emergency with complaints of acute febrile illness, breathlessness with cough, easy fatigability and accelerated hypertension (200/120 mm Hg at the time of admission) requiring ICU admission. On admission, relevant investigations are done. On physical examination, he appeared to be extremely pale. Vitals signs were: HR (144 bpm), BP (200/120 mm Hg), SpO₂: 84% on RA (95% with oxygen support), and Temperature: 103°F. The patient had a fever, tachycardia, accelerated hypertension,
and shortness of breath. On systemic examination, bilateral basal crepitations were found in the respiratory system. The blood report showed severe anaemia with Hb-4.9g/dL. Immediately, three units of PRBC were transfused and put on dialysis. Correction of Vitamin B12(114) was given. Peripheral smear showed early macrocytic anaemia with relative neutrophilia. HRCT results showed extensive patchy areas of ground glass opacifications with air space and opacification in the bilateral lung parenchyma (left >right side), suggesting pneumonia. 2D ECHO showed tachycardia (+), no definitive RWMA, and suitable LV systolic function with LVEF- 55%. The confirmatory diagnosis was an acute febrile illness, lower respiratory tract infection, bilateral pneumonitis, severe anaemia, chronic kidney disease stage 5, IgA nephropathy, seizure disorder, and accelerated hypertension. He was treated with appropriate IV antibiotics, antacids, nebulization, Oxygenation, and other supportive measures during the hospital stay. Meanwhile, he was dialyzed adequately as a life-saving treatment. As the patient was symptomatically better and hemodynamically stable, he was discharged with advice. The progress chart of the patient is as follows:

Day 1 (28/09/2022): At 1 PM, the patient’s vitals were as follows: HR (144 bpm), BP (200/120 mm Hg), SpO2: 84% on RA (95% with oxygen support) and Temperature: 103°F and severely anemic, his Hb level being a mere 4.9 gm/dL. Following this, he was admitted to ICU and was given Inj. MAGNEX FORTE 1.5 gms IV BD, Tab. DOLO 650 mg, Neb. DUOULIN Q6H and Neb. BUDECORT Q8H along with 1st dose of inj. Vancomycin 1 gm and Inj. Amikacin 500 mg. Arrangement of 3 units of PRBC transfusion was done. The patient was then advised for USG abdomen, chest X-ray, and 2D ECHO. At 4:30 PM, 2D ECHO reports indicated that the patient was tachycardic with a heart rate of 138 bpm and concentric LVH. Chest X-Ray reports showed bloodstream infection with fluid overload, and B/L quad infiltrates suggestive of pulmonary edema with B/L severe crepits and rhonchi sounds being prominent. At 5 PM, arterial blood gas analysis was done: HCO3 (35.9), Spo2 (96.2%), BF (1.6), pH (7.49), PaO2 (77.7), PaCO2 (32.2), Lactate (0.4), Sodium (142 mmol/L) and potassium (4.1 meq/L). The patient was kept on a ventilator with NIV FiO2 40 % (2:2: HS).

Day 2 (29/09/2022): At 8:30 AM, the patient reviewed symptomatically with complaints of cough and worked breathing reduced. Vitals were as follows: HR (108 bpm), BP (190/120 mm Hg), SpO2 (96% with 2L Oxygen), and afebrile, RS: Crepts were heard along with occasional rhonchi, and he was conscious and oriented. To discuss HRCT films, the patient was advised to RT-PCR/H1N1 swab and repeat ECHO when HR <100 bpm. At 9:10 AM, the vitals were: HR (132 bpm), BP (175/96 mm Hg), and SpO2 (96% with 5L oxygen). Laboratory investigations were as follows: Hb (7.86), Chloride (111 mmol/L), LDH (382), decreased Vit B12 (114 pg/ml), raised creatinine and reticulocyte levels (4.60 mg/dL and 3.5% respectively). The patient was stool examined for occult blood and administered Inj. ELDERVITA 12 mg OD for three days (weekly once), 1 unit of PRBC during hemodialysis along with leucocyte filter/UF 1000/, Inj. AMIGO PLUS, Tab. DOLO 650 mg SOS. The patient was severely anemic (Hb- 7.80). ECG and peripheral smear showed sinus tachycardia and early macrocytic anaemia with neutrophilia, vitals were stable, cough and dyspnea reduced, SpO2 (95% with 2L oxygen), chest X-Ray film showed non-dependent ground glass opacities suggestive of atypical pneumonia. The patient was given Cap. Tamiflu 75 mg OD. At 9:45 PM, Hb (7.8 gm/dL), HR (121 bpm), and RT-PCR reports were negative. CT score was 15/25, and HRCT showed multiple patchy areas of ground glass opacification. USG of abdomen reports showed B/L small kidneys with grade 2 medical renal disease with the right and left kidney measuring 7.8 cms* 70 mm and 8 cm* 80 mm, respectively, mild parenchymal thinning, and moderate increased cortical echotexture.

Day 3 (30/09/2022): At 9:15 AM, the measured vitals were as follows- HR (112 bpm), BP (153/106 mmHg), SpO2 (97%), afebrile temperature and Hb was 8.69. The patient was planned for protoclysis enema, hemodialysis with a high protein diet, SLED/4hrs/saline, no heparin/UF 1000, 1 unit of PRBC with leucocyte filter during hemodialysis, and Inj. AMIGO PLUS 200 mg IV during hemodialysis. At 4:30 PM, vitals were as follows- HR (127 bpm), BP (130/90 mm Hg). The patient was also given a TAB. MINIPRESS XL 10 mg BD, TAB. NICARDIA R 20 mg tid, TAB. CARDIVAS 5 mg P/O, SYP. LACTULOSE 15 ml P/O BD and TAB. DOLO 650 mg Q6H SOS.

Day 4 (01/10/2022): At 9:50 AM, the vitals were as follows- HR (105 bpm), BP (140/90 mm Hg), SpO2 (95% on RA), and Hb level was 8.90. Hemodialysis was done with potassium dialysate 4 mEq, Inj. KCl 20 mEq IV during hemodialysis in 100 ml over 3 hours. Inj. AMIGO PLUS (1-unit PRBC during HD) with Inj. VITNEURIN 1 amp in 50 ml and Inj. VANCOMYCIN 50 ml over 15 hrs, Inj. PAN 40 mg IV OD, TAB. MINIPRESS XL 10 mg BD, TAB. NICARDIA R 20 mg tid, TAB. CARDIVAS 5 mg P/O, SYP. LACTULOSE 15 ml P/O BD and TAB. DOLO 650 mg Q6H SOS, NEB. DUOULIN, NEB. BUDECORT, TAB. LEVIPIL 50 mg P/O BD, TAB. SELBO 400 mg 400 mg BD, Inj. MEROPENEM 500 mg IV, Inj. LEVODAY 250 mg IV (in 50 ml dilution) OD.

Day 5 (02/10/2022): At 10:30 AM, the vitals were as follows- HR (126 bpm), BP (160/100 mm Hg), SpO2 (97%), and Hb level was 9.22. The patient was administered Inj. VITNEURIN IV in 50 ml NS over 1 hour. He was given Inj. PAN 40 mg IV OD, TAB. MINIPRESS XL 10 mg BD, TAB. NICARDIA R 20 mg tid, TAB. CARDIVAS 5 mg P/O, SYP. LACTULOSE 15 ml P/O BD and TAB. DOLO 650 mg Q6H SOS, NEB. DUOULIN, NEB. BUDECORT, TAB. LEVIPIL 50 mg P/O BD, TAB. SELBO 400 mg 400 mg BD, Inj. MEROPENEM 500 mg IV, Inj. LEVODAY 250 mg IV (in 50 ml dilution) OD.

Day 6 (03/10/2022): At 9:30 AM, the vitals were as follows- HR (80 bpm), BP (170/110 mm Hg), Hb (8.83 gm/dL), raised S. Creatinine (6.8 mg/dL) and raised chloride levels (112 mmol/L). He was given Inj. PAN 40 mg IV OD, TAB. MINIPRESS XL 10 mg BD, TAB. NICARDIA R 20 mg tid, TAB. CARDIVAS 5 mg P/O, SYP. LACTULOSE 15 ml P/O BD and
IgA Nephropathy is a common glomerular disease and a significant cause of renal failure. Furthermore, it may rarely initially just exhibit ESRD-related hypertensive emergency symptoms. Patients are likely to experience a progressive course that results in ESRD; hence early detection and intervention are crucial.

REFERENCES


CONCLUSION

The most prevalent cause of end-stage renal disease in people with primary glomerulopathy is IgA nephropathy, the most prevalent form of primary glomerulonephritis worldwide [4]. During the second and third decades of life, the incidence significantly rises [7]. It is recognized that deposition of IgA with a majority of Lambda light chains occurs in the renal mesangium, though the pathogenesis is not entirely understood [8]. Patients typically present with gross haematuria following an upper respiratory tract infection or they may present with microscopic haematuria with varying degrees of proteinuria [9]. In more severe cases, nephrotic-range proteinuria is frequently observed. Following an episode of a non-specific upper respiratory tract infection, episodic haematuria is the characteristic sign [10]. IgA nephropathy exhibits a wide range of clinical and pathological features. Clinical features range from asymptomatic haematuria to Rapidly Progressive Glomerulonephritis (RPGN). Clinically, RPGN is indicated by a sudden drop in glomerular filtration rate (GFR) of at least 50% over a brief time, ranging from a few days to three months [11]. Thrombotic microangiopathy can also be found in IgA nephropathy due to malignant hypertension and indicates a poor renal outcome, as seen in our case. Increased serum creatinine (Cr), decreased glomerular filtration rate (GFR), hypertension (blood pressure > 140/90 mmHg), and chronic proteinuria are some of the clinical and laboratory findings that might assist in stratifying the severity of the disease at the time of diagnosis [12].

Initial and subsequent renal function may be within normal ranges for a significant time [11]. Renal biopsy is the gold standard for diagnosis since it reveals mesangium proliferation with IgA deposits under immunofluorescence and electron microscopy [13]. The development of ESRD (end-stage renal disease), which affects 15% to 20% of patients by the age of 10, and 20% to 50% of patients by the age of 20, has been shown in long-term follow-up studies of the biopsy-verified cases [14]. Patients with greater systolic blood pressure, lower GFR, haemoglobin, and serum albumin levels at baseline are more at risk of developing ESRD, according to a study by Xie J et al. [15].

Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

For any questions related to this article, please reach us at: globalresearchonline@rediffmail.com
New manuscripts for publication can be submitted at: submit@globalresearchonline.net and submit_ijpsrr@rediffmail.com

International Journal of Pharmaceutical Sciences Review and Research
Available online at www.globalresearchonline.net

©Copyright protected. Unauthorised republication, reproduction, distribution, dissemination and copying of this document in whole or in part is strictly prohibited.